ストックスクリーナーアプリを入手
7.75
2.02%
-0.16
アフターアワーズ：
7.54
-0.21
-2.71%
前日終値:
$7.91
開ける：
$7.9
24時間の取引高:
129.29K
Relative Volume:
0.33
時価総額：
$75.35M
収益：
$21.73M
当期純損益:
$-91.17M
株価収益率:
-10.47
EPS:
-0.74
ネットキャッシュフロー:
$-286.43M
1週間 パフォーマンス:
-0.64%
1か月 パフォーマンス:
-7.07%
6か月 パフォーマンス:
-66.59%
1年 パフォーマンス:
-62.01%
1日の値動き範囲:
$7.70
$8.2196
1週間の範囲:
$7.25
$8.24
52週間の値動き範囲:
$5.80
$38.40
Bluebird Bio Inc Stock (BLUE) Company Profile
名前
Bluebird Bio Inc
セクター
電話
339-499-9300
住所
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
BLUE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
7.75 | 75.35M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-11-15 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-08-15 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-12-11 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2023-12-08 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | 開始されました | Cantor Fitzgerald | Neutral |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-07-19 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-06-01 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-04-28 | 開始されました | JP Morgan | Overweight |
| 2023-03-07 | 開始されました | Robert W. Baird | Outperform |
| 2022-08-05 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-08-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-03-07 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2021-11-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-11-08 | 繰り返されました | Canaccord Genuity | Hold |
| 2021-11-08 | ダウングレード | Goldman | Neutral → Sell |
| 2021-11-08 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | 繰り返されました | Wedbush | Neutral |
| 2021-11-08 | 繰り返されました | Wells Fargo | Equal Weight |
| 2021-08-10 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | ダウングレード | Goldman | Buy → Neutral |
| 2021-08-10 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | 再開されました | William Blair | Mkt Perform |
| 2021-08-09 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | ダウングレード | Berenberg | Buy → Hold |
| 2021-03-10 | アップグレード | Mizuho | Neutral → Buy |
| 2021-02-17 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-02-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-02-16 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-02-16 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | ダウングレード | Maxim Group | Buy → Hold |
| 2020-11-11 | 開始されました | Berenberg | Buy |
| 2020-11-05 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-11-05 | ダウングレード | Stifel | Buy → Hold |
| 2020-11-02 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | 開始されました | Mizuho | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-03-27 | アップグレード | Stifel | Hold → Buy |
| 2020-02-19 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | 再開されました | BofA/Merrill | Buy |
| 2020-02-03 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-12-13 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-11-26 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-04 | アップグレード | Wedbush | Neutral → Outperform |
| 2019-10-01 | 開始されました | Stifel | Hold |
| 2019-08-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | アップグレード | Maxim Group | Hold → Buy |
すべてを表示
Bluebird Bio Inc (BLUE) 最新ニュース
bluebird bio (NASDAQ:BLUE) Share Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Sickle Cell Treatment Market Focusing on Trends and Innovations - openPR
bluebird bio Q4 EPS Estimate Increased by Leerink Partnrs - MarketBeat
Cantor Fitzgerald Predicts bluebird bio FY2025 Earnings - MarketBeat
Sickle Cell Disease Pipeline 2024: Comprehensive Clinical - openPR
Bluebird Bio presents long-term data on LYFGENIA gene therapy for SCD - MSN
Cantor Fitzgerald Estimates bluebird bio FY2025 Earnings - MarketBeat
Long-Term Investors in bluebird bio Inc (NASDAQ: BLUE) should - openPR
bluebird bio, Inc. (NASDAQ:BLUE) Short Interest Update - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Adrenoleukodystrophy Drugs Market Is Booming Worldwide - openPR
Brokerages Set bluebird bio, Inc. (NASDAQ:BLUE) PT at $49.14 - Defense World
FDA investigating safety risks of bluebird's Skysona - MSN
bluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) & bluebird bio (NASDAQ:BLUE) Head-To-Head Survey - Defense World
National Resilience to lay off 120 in North Carolina - Manufacturing Dive
Bluebird bio CEO Andrew Obenshain sells $1,293 in stock By Investing.com - Investing.com Nigeria
Bluebird bio chief medical officer sells $175 in stock By Investing.com - Investing.com Australia
Bluebird bio CEO Andrew Obenshain sells $1,293 in stock - Investing.com
Bluebird bio chief medical officer sells $175 in stock - Investing.com
bluebird bio (NASDAQ:BLUE) Stock Price Passes Below 200-Day Moving AverageHere's Why - MarketBeat
Gene Therapy Market Generated Opportunities, Future Scope by 2031 | GlaxoSmithKline plc, Bluebird Bio, Inc. - openPR
Biotech manufacturer plans to cut 120 jobs in Durham - WRAL News
Hemoglobinopathies Market Projected to Show Strong Growth| - openPR
Gene Therapy Market Generated Opportunities, Future Scope - openPR
Investors Don't See Light At End Of bluebird bio, Inc.'s (NASDAQ:BLUE) Tunnel And Push Stock Down 38% - Simply Wall St
Barclays Issues Positive Forecast for bluebird bio (NASDAQ:BLUE) Stock Price - Defense World
bluebird bio's SWOT analysis: gene therapy stock faces cash crunch amid launch - Investing.com
Barclays Forecasts Strong Price Appreciation for bluebird bio (NASDAQ:BLUE) Stock - MarketBeat
bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
bluebird bio, Inc. (NASDAQ:BLUE) Sees Significant Decrease in Short Interest - MarketBeat
Once high-flying, bluebird bio now faces an uncertain future - The Business Journals
Gene Therapy Market Analysis,Growth, Insights and Future Outlook | Exactitude Consultancy - GlobeNewswire Inc.
Five things you need to know, and baby mind control - The Business Journals
Bluebird Bio (BLUE) Shares Surge Amid Market Activity - GuruFocus.com
2seventy bio: All In On ABECMA Multiple Myeloma Treatment - Seeking Alpha
bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Gene Therapy For Rare Disease Market Overall Study Report - openPR
bluebird bio, Inc. (NASDAQ:BLUE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Gene Therapy Market Huge Growth in Future Scope 2024-2031 | - openPR
Baird cuts bluebird bio price target on near-term dilution By Investing.com - Investing.com Canada
bluebird bio (NASDAQ:BLUE) Shares Up 15.3%Time to Buy? - MarketBeat
Baird cuts bluebird bio price target on near-term dilution - Investing.com
Cell and Gene Therapy Drug Delivery Devices Market to Witness - openPR
Bluebird Bio's SWOT analysis: gene therapy firm's stock faces cash crunch By Investing.com - Investing.com South Africa
Bluebird Bio's SWOT analysis: gene therapy firm's stock faces cash crunch - Investing.com
Bluebird Bio Inc (BLUE) 財務データ
収益
当期純利益
現金流量
EPS
3.95%
2.39%
大文字化:
|
ボリューム (24 時間):